DeutschNewstral
Article
bizjournals.com on 2015-05-06 22:38
One year, nearly $400M and a plan to improve drug testing: This Seattle biotech is roaring
Related news
- Former Zillow CFO heads to Seattle biotechbizjournals.com
Seattle biotech Adaptive buys San Francisco firmseattletimes.com- Seattle biotech Stratos Genomics racks up $30M for DNA sequencingbizjournals.com
Seattle brothers expand billion-dollar biotech company’s focus to include COVIDSeattle Times- Biotech leaders sound off on how to create anchor companies, stable ecosystem in Seattlebizjournals.com
- Boulder biotech acquires Seattle companybizjournals.com
- Expedia move to Amgen campus underscores need for biotech lab space in Seattlebizjournals.com
- Seattle biotech Adaptive lives up to its name, pivots toward drug developmentbizjournals.com
- Tech vs. biotech: VC heavyweights Madrona, Arch face off over how to dominate Seattlebizjournals.com
- Maryland company to spin out new publicly traded Seattle cancer biotechbizjournals.com
- Seattle biotech outpaces Washington's public companiesbizjournals.com
- Seattle biotech PhaseRx files to go publicseattletimes.com
- Seattle biotech expands portfolio with Boston acquisitionbizjournals.com
- Seattle Genetics buys biotech factory in Bothellseattletimes.com
- Seattle biotech Silverback Therapeutics prices upsized IPOseattletimes.com
- Seattle biotech Oncothyreon names new CEObizjournals.com
- Seattle biotech Faraday Pharmaceuticals names new CEObizjournals.com
- Seattle Genetics operations chief resigns to lead stealthy Seattle biotechbizjournals.com
- $400M funding round prompts Seattle freight startup to double spacebizjournals.com
- Seattle-based biotech startup Sana raises $821 millionSeattle Times